TheEdgeResearch
Home / Stocks / EW

Edwards Lifesciences Corporation (EW)

NYSE Healthcare Medical - Devices
$88.26 ▲ +0.01%
Market Cap
$50.82B
Sector
Healthcare
Industry
Medical - Devices
Beta
0.85
52-Wk Range
72.3-96.29
CEO
Bernard J. Zovighian
Country
US
Currency
USD

Edwards Lifesciences Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $88.26, up 0.01% on the session, giving a market capitalisation of $50.82B. On trailing twelve-month figures it carries a trailing P/E of 50.72, a net margin of 15.4%. Its beta of 0.85 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
50.72
Price / Sales
7.80
Price / Book
4.79
EV / EBITDA
31.57
Gross margin
78.0%
Operating margin
28.1%
Net margin
15.4%
Return on equity
Debt / equity
0.07
Current ratio
4.52
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
16,000
IPO date
2000-03-27
Headquarters
Irvine, CA, US
About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Comparable companies

Edwards Lifesciences Corporation is most often compared with the following Healthcare names:

AALCARGXBDXBRKRCAHDXCMHLNSTEVEEV
More research on EW
EW technical analysis EW TheEdge Score Compare against peers
Open full interactive analysis & DCF →